24 oktober 2006: Bron: 1: Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1330-7.

Patienten met keelkanker behandeld met radiochemotherapie (chemo : cisplatin en 5-FU) hebben met L-alanyl-L-glutamine in vergelijking met placebo minder last van mucositis. Het verschil is statistisch significant. In de placebogroep kreeg 67% last van ernstige mucositis en in de groep die L-alanyl-L-glutamine kreeg slechts 14%.

Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer.Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar ME, Roth B, Negretti G, Sheinker B, Uchima P.
Translational Research Unit, Instituto de Oncologia Angel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina. lcerchietti@gmail.com

PURPOSE: We performed this double-blinded, placebo-controlled study to determine the safety and efficacy of L-alanyl-L-glutamine in the prevention of mucositis in patients with head-and-neck cancer.

METHODS AND MATERIALS: Thirty-two patients with head-and-neck cancer were treated with chemoradiotherapy (CRT) (radiotherapy daily up to 70 Gy plus cisplatin/5-fluoruracil once a week) and were asked to participate. Twenty-nine patients received the CRT schedule and were double-blindly assigned to receive either intravenous L-alanyl-L-glutamine 0.4 g/kg weight/day or an equal volume of saline (placebo) during chemotherapy days.

RESULTS: Fourteen patients received L-alanyl-L-glutamine and 15 received placebo. Mucositis was assessed by the Objective Mucositis Score (OMS) and the World Health Organization (WHO) grading system. There was a significant difference in incidence of mucositis developed in patients receiving placebo compared with those who received L-alanyl-L-glutamine (p = 0.035). The number of patients with severe objective mucositis (OMS >1.49) was higher in the placebo group compared with the L-alanyl-L-glutamine group (67% vs. 14%, p = 0.007). L-alanyl-L-glutamine patients experienced less pain (three highest Numeric Rating Scale scores of 1.3/10 vs. 6.3/10 respectively, p = 0.008) and need for feeding tubes (14% vs. 60% respectively, p = 0.020) compared with placebo patients. No adverse effects related to the drug or the infusions were noted in either group.

CONCLUSION: For patients with head-and-neck cancer receiving CRT, intravenous L-alanyl-L-glutamine may be an effective preventive measure to decrease the severity of mucositis.

PMID: 16765532 [PubMed - indexed for MEDLINE]

Plaats een reactie ...

Reageer op "L-alanyl-L-glutamine vermindert bijwerkingen zoals mucositis, veroorzaakt door chemo plus bestraling bij patienten met keelkanker"


Gerelateerde artikelen
 

Gerelateerde artikelen

Aspirine zou kanker in mond >> Antioxidanten - Beta caroteen >> Betacaroteen remt progressie >> Calendula gel vermindert ontstekingen >> Chinese kruiden hebben vaak >> Groenten en fruit en een vezelrijk >> Immuunstimulerende voedingsupplement >> Interferon Alfa-2a en isotretinoin >> Interferon, retinoid - vitamine >> L-alanyl-L-glutamine vermindert >>